Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis

References

• Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23–26.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Lindberg M, Isacson D, Bingefors K. Self-reported skin diseases, quality of life and medication use: a nationwide pharmaco-epidemiological survey in Sweden. Acta Derm Venereol. 2014;94(2):188–191.
   PubMed Web of Science ®Google Scholar
• Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–667.
   PubMed Web of Science ®Google Scholar
• Schmid-Ott G, Kunsebeck HW, Jager B, et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol. 2005;85(1):27–32.
   PubMed Web of Science ®Google Scholar
• Henes JC, Ziupa E, Eisfelder M, et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. Rheumatol Int. 2014;34(2):227–234.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87–113.
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987–1019.
   PubMed Web of Science ®Google Scholar
• Kolios AG, Yawalkar N, Anliker M, et al. Swiss S1 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology. 2016;232(4):385–406.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr., Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19(1 Pt 1):145–156.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–485.
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013;40(9):683–695.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish psoriasis group of the Spanish academy of dermatology and venereology. Actas Dermosifiliogr. 2013;104(8):694–709.
   PubMedGoogle Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–636.
   Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
   PubMed Web of Science ®Google Scholar
• Hamadah IR, Al Raddadi AA, Bahamdan KA, et al. Saudi practical guidelines on biologic treatment of psoriasis. J Dermatolog Treat. 2015;26(3):223–229.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European league against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12.
   PubMed Web of Science ®Google Scholar
• Vieira-Sousa E, Machado PM, Costa J, et al. Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis – 2015 update. Acta Reumatol Port. 2015;40(3):275–290.
   PubMed Web of Science ®Google Scholar
• Coates LC, Tillett W, Chandler D, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology. 2013;52(10):1754–1757.
   PubMed Web of Science ®Google Scholar
• Marques Pinto G, Filipe P. Guidelines for high-quality use of biologic therapies in adults with plaque psoriasis. Acta Med Port. 2012;25(2):125–141.
   PubMed Web of Science ®Google Scholar
• FDA approves Cimzia for plaque psoriasis. 2018. Published 2018 May 29. [cited 2018 Aug 20]. Available from: https://www.psoriasis.org/advance/fda-approves-cimzia-for-plaque-psoriasis
   Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29(1):13–18.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomised controlled trials. Br J Dermatol. 2018;179(3):615–622.
   Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–1560.
   PubMed Web of Science ®Google Scholar
• Xeljanz (tofacitinib) prescribing information. New York (NY): Pfizer Labs; 2012. Available from: http://labeling.pfizer.com/showlabeling.aspx?id=959
   Google Scholar
• Weise M, Bielsky MC, De Smet K, et al. Biosimilars – why terminology matters. Nat Biotechnol. 2011;29(8):690–693.
   PubMed Web of Science ®Google Scholar
• Patel P, King CR, Feldman SR. Biologics and biosimilars. J Dermatolog Treat. 2015;26(4):299–302.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Ostor AJ. Immune-Mediated Inflammatory Diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–298.
   PubMed Web of Science ®Google Scholar